Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study

Shan Luo,C. Mary Schooling,Ian Chi Kei Wong,Shiu Lun Au Yeung
DOI: https://doi.org/10.1007/s00125-020-05243-z
IF: 8.2
2020-08-04
Diabetologia
Abstract:Whether metformin reduces cardiovascular or cancer risk is unclear owing to concerns over immortal time bias and confounding in observational studies. This study evaluated the effect of AMP-activated protein kinase (AMPK), the target of metformin, on risk of cardiovascular disease and cancer.
endocrinology & metabolism
What problem does this paper attempt to address?